GlobeNewswire Inc | Dec 3, 2020 09:15AM EST

December 03, 2020

BERWYN, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers disease (AD), Parkinsons disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the NewYorkAcademyofSciences Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference on Friday, December 4, 2020.

Dr. Maccecchinis presentation, Targeting Increased Levels of Neurotoxic Proteins in Down Syndrome, Alzheimers and Parkinsons Animals Normalized Axonal Transport, Cognition and Function, will highlight the Companys data that demonstrates by lowering amyloid, tau, and alpha-synuclein, the Companys lead candidate, ANVS401, restores axonal transport and nerve cell health.

Our approach to neurodegeneration is unique when compared to the long list of failed trials exclusively targeting amyloid, stated Dr. Maccecchini. I am excited to share our promising data with the conference attendees at this first major event of its type dedicated to non-amyloid approaches to AD.

ANVS401 inhibits more than one neurotoxic protein and, thereby, improves axonal transport and reverses the toxic cascade leading to nerve cell death. The Company is presently in two ongoing double-blind, placebo-controlled Phase 2a studies that were designed to measure the toxic cascade that leads to nerve cell death and expects preliminary data in both AD and PD patients in the first half of 2021.

About Annovis Bio

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimers disease (AD), Parkinsons disease (PD) and Alzheimers in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the companys website:www.annovisbio.com.

Forward-Looking Statements

Statements in this press release contain forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as anticipate, expect, believe, will, may, should, estimate, project, outlook, forecast or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled Risk Factors in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dave Gentry, CEO RedChip Companies Inc. 407-491-4498Dave@redchip.com

SOURCE: Annovis Bio, Inc.